Personalis Inc Quick Ratio (PSNL) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Personalis Inc   (NASDAQ: PSNL)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Personalis Inc 's Quick Ratio

PSNL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 5.17 below Personalis Inc average.

Within Medical Laboratories industry 9 other companies have achieved higher Quick Ratio than Personalis Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 739, from total ranking in the second quarter 2026 at 874.

Explain Quick Ratio?
How much Cash & cash equivalents PSNL´s has?
What are PSNL´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PSNL/financial-strength
https://api.csimarket.com/api/v1/companies/PSNL/fundamentals
https://api.csimarket.com/api/v1/companies/PSNL/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
PSNL Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 36.28 %
Y / Y Cash & cash equivalent Change 69.31 %
Quick Ratio MRQ 5.17
PSNL's Total Ranking # 739
Seq. Current Liabilities Change 6.23 %
Seq. Cash & cash equivalent Change -8.47 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Medical Laboratories Industry # 10
Healthcare Sector # 295
Overall Market # 790


Quick Ratio Statistics
High Average Low
11.51 5.49 1.26
(Sep 30 2021)   (Dec 31 2018)




Financial Statements
Personalis Inc 's Current Liabilities $ 49 Millions Visit PSNL's Balance sheet
Personalis Inc 's Cash & cash equivalent $ 255 Millions Visit PSNL's Balance sheet
Source of PSNL's Sales Visit PSNL's Sales by Geography


Cumulative Personalis Inc 's Quick Ratio

PSNL's Quick Ratio for the trailling 12 Months

PSNL Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 35.25 %
Y / Y Cash & cash equivalent TTM Growth 44.93 %
Quick Ratio TTM 5.77
Total Ranking TTM # 3880
Seq. Current Liabilities TTM Growth 8.14 %
Seq. Cash & cash equivalent TTM Growth 11.56 %


On the trailing twelve months basis PSNL Cash & cash equivalent soared by 69.31 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Personalis Inc 's Quick Ratio to 5.77, above PSNL average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 34 other companies have achieved higher Quick Ratio than Personalis Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3610 to 3880.

Explain Quick Ratio?
How much Cash & cash equivalents PSNL´s has?
What are PSNL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Medical Laboratories Industry # 35
Healthcare Sector # 885
Within the Market # 3880


trailing twelve months Quick Ratio Statistics
High Average Low
3.01 2.15 1.11
(Dec 31 2021)   (Jun 30 2020)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Medical Laboratories Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Aclarion Inc   13.58 $ 14.188  Millions$ 1.044  Millions
Celcuity Inc   12.38 $ 642.703  Millions$ 51.925  Millions
Miragen Therapeutics Inc   11.70 $ 955.206  Millions$ 81.673  Millions
Billiontoone Inc   9.26 $ 561.512  Millions$ 60.637  Millions
Maxcyte inc   6.36 $ 101.280  Millions$ 15.916  Millions
Personalis Inc   5.17 $ 254.841  Millions$ 49.274  Millions
Veracyte Inc   4.40 $ 370.532  Millions$ 84.209  Millions
Castle Biosciences Inc   4.11 $ 277.665  Millions$ 67.612  Millions
Fulgent Genetics Inc   4.07 $ 292.739  Millions$ 71.877  Millions
Omniab Inc   3.81 $ 64.210  Millions$ 16.853  Millions
Guardant Health Inc   2.75 $ 1,026.848  Millions$ 373.165  Millions
Incyte Corporation  2.68 $ 3,854.572  Millions$ 1,437.818  Millions
Exagen Inc   2.14 $ 28.092  Millions$ 13.100  Millions
Biodesix Inc   1.99 $ 28.409  Millions$ 14.248  Millions
Caredx Inc   1.80 $ 250.480  Millions$ 138.975  Millions
Butterfly Network Inc   1.80 $ 122.301  Millions$ 67.987  Millions
Sera Prognostics Inc   1.80 $ 44.089  Millions$ 24.527  Millions
Radnet Inc   1.11 $ 797.880  Millions$ 716.642  Millions

Date modified: 2026-11-06T12:59:38+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.